BR9712808A - Indol-3-glioxilamidas n-substituìdas com efeito antiasmático, anti-alérgico e imunossupressor/imunomodulador - Google Patents

Indol-3-glioxilamidas n-substituìdas com efeito antiasmático, anti-alérgico e imunossupressor/imunomodulador

Info

Publication number
BR9712808A
BR9712808A BR9712808-2A BR9712808A BR9712808A BR 9712808 A BR9712808 A BR 9712808A BR 9712808 A BR9712808 A BR 9712808A BR 9712808 A BR9712808 A BR 9712808A
Authority
BR
Brazil
Prior art keywords
immunosuppressive
substituted
glyoxylamides
antiasthmatic
indol
Prior art date
Application number
BR9712808-2A
Other languages
English (en)
Other versions
BR9712808B1 (pt
Inventor
Guillaume Lebaut
Cecilia Menciu
Bernhard Kutscher
Peter Emig
Stefan Szelenyi
Brune Kay
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of BR9712808A publication Critical patent/BR9712808A/pt
Publication of BR9712808B1 publication Critical patent/BR9712808B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Patente de Invenção:<B>"INDOL-3-GLIOXILAMIDAS N-SUBSTITUìDAS COM EFEITO ANTIASMáTICO, ANTIALéRGICO E IMUNOSSUPRESSOR/IMUNOMODULADOR"<D>. A invenção refere-se a novas indol-3-glioxilamidas N-substituídas, processos para a sua preparação e seu emprego farmacêutico. Os compostos apresentam efeitos antiasmáticos, antialérgicos e imunossupressivos/imunomoduladoros.
BRPI9712808-2A 1996-09-06 1997-08-16 indol-3-glioxilamidas n-substituìdas, bem como aplicação, medicamento e processo para a preparação das mesmas. BR9712808B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19636150A DE19636150A1 (de) 1996-09-06 1996-09-06 N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
PCT/EP1997/004474 WO1998009946A1 (de) 1996-09-06 1997-08-16 N-substituierte indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender wirkung

Publications (2)

Publication Number Publication Date
BR9712808A true BR9712808A (pt) 1999-11-23
BR9712808B1 BR9712808B1 (pt) 2009-05-05

Family

ID=7804772

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9712808-2A BR9712808B1 (pt) 1996-09-06 1997-08-16 indol-3-glioxilamidas n-substituìdas, bem como aplicação, medicamento e processo para a preparação das mesmas.

Country Status (27)

Country Link
US (4) US6008231A (pt)
EP (1) EP0931063B3 (pt)
JP (1) JP3296437B2 (pt)
KR (1) KR100516321B1 (pt)
CN (3) CN100376554C (pt)
AR (1) AR008630A1 (pt)
AT (1) ATE342889T1 (pt)
AU (1) AU726521B2 (pt)
BR (1) BR9712808B1 (pt)
CA (1) CA2215013C (pt)
CZ (1) CZ302301B6 (pt)
DE (2) DE19636150A1 (pt)
DK (1) DK0931063T5 (pt)
ES (1) ES2276433T7 (pt)
HK (3) HK1021641A1 (pt)
HU (1) HU227797B1 (pt)
IL (1) IL127798A (pt)
NO (2) NO314725B3 (pt)
NZ (1) NZ334476A (pt)
PT (1) PT931063E (pt)
RU (1) RU2237661C2 (pt)
SK (1) SK285618B6 (pt)
TR (1) TR199900469T2 (pt)
TW (1) TW550256B (pt)
UA (1) UA60312C2 (pt)
WO (1) WO1998009946A1 (pt)
ZA (1) ZA977475B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
ID27884A (id) * 1998-03-31 2001-05-03 Inst For Pharm Discovery Inc Asam-asam indolealkanoat yang disubstitusikan.
CZ302588B6 (cs) * 1998-04-02 2011-07-27 Ziopharm Oncology, Inc. Použití N-substituovaného indol-3-glyoxylamidu pro výrobu léciva
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE19946301A1 (de) 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE19818964A1 (de) * 1998-04-28 1999-11-04 Dresden Arzneimittel Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
ES2262072T3 (es) * 1998-04-28 2006-11-16 Elbion Ag Derivados de indol y su utilizacion como inhibidores de la fosfodiesterasa 4.
DE19917504A1 (de) * 1999-04-17 2000-10-19 Dresden Arzneimittel Verwendung von Hydroxyindolen, die Inhibitoren der Phosphodiesterase 4 sind, zur Therapie chronisch obstruktiver Lungenerkrankungen
EP2193808A1 (en) 1999-08-21 2010-06-09 Nycomed GmbH Synergistic combination
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
AU2002323474B2 (en) * 2001-09-13 2006-10-05 Synta Pharmaceuticals Corp 3-glyoxlylamideindoles for treating cancer
US6903104B2 (en) * 2001-12-06 2005-06-07 National Health Research Institutes Indol-3-YL-2-oxoacetamide compounds and methods of use thereof
CN1684685A (zh) * 2002-07-26 2005-10-19 药物研发有限责任公司 取代的吲哚基链烷酸衍生物和含有其的治疗糖尿病并发症用配制剂
US7122674B2 (en) * 2002-08-01 2006-10-17 Elbion Ag Process for preparing high-purity hydroxyindolylglyoxylamides
DE10253426B4 (de) * 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10318611A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318609A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318610A1 (de) 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
CA2587276A1 (en) * 2004-11-08 2006-05-18 Baxter International Inc. Nanoparticulate compositions of tubulin inhibitor compounds
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
JP2006247963A (ja) * 2005-03-09 2006-09-21 Oji Paper Co Ltd インクジェット記録用シート
EP2363128B1 (en) * 2005-03-11 2016-02-17 Vertex Pharmaceuticals Incorporated Indole modulators of ATP-binding cassette transporters
US7404381B2 (en) 2005-04-29 2008-07-29 Tendix Development, Llc Radial impulse engine, pump, and compressor systems, and associated methods of operation
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US7598380B2 (en) * 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
CN102764440A (zh) 2006-07-05 2012-11-07 奈科明有限责任公司 用于治疗炎症性肺部疾病的HMG-CoA还原酶抑制剂与磷酸二酯酶4抑制剂的组合
EP2610244A1 (en) * 2006-08-07 2013-07-03 Ironwood Pharmaceuticals, Inc. Indole compounds
EP2066619A2 (en) * 2006-11-02 2009-06-10 Arete Therapeutics, INC. Soluble epoxide hydrolase inhibitors
EP2091532A1 (en) * 2006-11-28 2009-08-26 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
NZ789295A (en) 2009-04-29 2024-02-23 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
CN103827105B (zh) 2011-08-18 2016-08-17 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(cetp)抑制剂的取代的杂环胺化合物
CN103958511A (zh) 2011-09-27 2014-07-30 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
CN109000634B (zh) * 2018-06-04 2022-06-03 上海智蕙林医疗科技有限公司 一种导航对象行进路线的提醒方法和系统

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797258A (en) * 1955-04-11 1958-06-25 Upjohn Co 3-substituted indoles
GB944443A (pt) * 1959-09-25 1900-01-01
GB1028812A (en) * 1962-08-28 1966-05-11 Ici Ltd Indole derivatives
GB1089071A (en) * 1964-02-28 1967-11-01 Merck & Co Inc Indole derivatives
US3686213A (en) * 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
FR2689888B1 (fr) * 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
CZ82295A3 (en) * 1994-04-01 1995-12-13 Lilly Co Eli Derivative of 1h-indole-3-glyoxylamide and a pharmaceutical composition containing thereof
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
US7205299B2 (en) * 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect

Also Published As

Publication number Publication date
SK27199A3 (en) 1999-08-06
DE19636150A1 (de) 1998-03-12
ES2276433T7 (es) 2009-11-05
TW550256B (en) 2003-09-01
PT931063E (pt) 2007-02-28
EP0931063A1 (de) 1999-07-28
KR100516321B1 (ko) 2005-09-23
JP3296437B2 (ja) 2002-07-02
IL127798A0 (en) 1999-10-28
NO991071L (no) 1999-03-04
HK1123280A1 (en) 2009-06-12
DE59712752D1 (de) 2006-11-30
NO991071D0 (no) 1999-03-04
CA2215013A1 (en) 1998-03-06
CA2215013C (en) 2002-03-05
IL127798A (en) 2003-07-31
US6919344B2 (en) 2005-07-19
CN1227542A (zh) 1999-09-01
BR9712808B1 (pt) 2009-05-05
US20020161025A1 (en) 2002-10-31
US6008231A (en) 1999-12-28
WO1998009946A1 (de) 1998-03-12
CZ61699A3 (cs) 1999-06-16
ZA977475B (en) 1998-02-19
HU227797B1 (en) 2012-03-28
NZ334476A (en) 2000-05-26
CZ302301B6 (cs) 2011-02-09
CN1496980A (zh) 2004-05-19
DK0931063T3 (da) 2007-02-19
HUP9903741A2 (hu) 2000-04-28
TR199900469T2 (xx) 1999-05-21
ATE342889T1 (de) 2006-11-15
AU726521B2 (en) 2000-11-09
DK0931063T5 (da) 2010-01-11
RU2237661C2 (ru) 2004-10-10
SK285618B6 (sk) 2007-05-03
NO20030481D0 (no) 2003-01-30
HK1064379A1 (en) 2005-01-28
CN101219985B (zh) 2011-04-27
AR008630A1 (es) 2000-02-09
CN100488948C (zh) 2009-05-20
ES2276433T3 (es) 2007-06-16
HUP9903741A3 (en) 2001-01-29
HK1021641A1 (en) 2000-06-23
EP0931063B3 (de) 2009-04-08
NO314725B3 (no) 2009-03-09
CN101219985A (zh) 2008-07-16
KR20000068495A (ko) 2000-11-25
CN100376554C (zh) 2008-03-26
EP0931063B1 (de) 2006-10-18
AU726521C (en) 1998-03-26
AU4015897A (en) 1998-03-26
NO20030481L (no) 1999-03-04
UA60312C2 (uk) 2003-10-15
US20030207892A1 (en) 2003-11-06
NO314725B1 (no) 2003-05-12
JP2000505098A (ja) 2000-04-25
US6344467B1 (en) 2002-02-05

Similar Documents

Publication Publication Date Title
BR9712808A (pt) Indol-3-glioxilamidas n-substituìdas com efeito antiasmático, anti-alérgico e imunossupressor/imunomodulador
BR9916307A (pt) Derivados quinolina
ID28003A (id) Turunan-turunan adamantana
FR2744449B1 (fr) Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
BR9713363A (pt) Epotilonas c, d, e e f, preparação e composições
ATE2667T1 (de) Antidepressiv wirkende derivate des trans-4phenyl-1,2,3,4-tetrahydro-1-naphthalin-amins und pharmazeutische zusammensetzungen daraus.
NO964212D0 (no) Ny oral farmasöytisk doseringsform
BR9713499A (pt) Halogenopirimidinas
NO982580D0 (no) Nye taxoider, deres fremstilling samt farmas°ystiske preparater inneholdende taxoidene
IL82265A (en) N-(2&#39;-aminophenyl)-benzamide derivatives,their preparation and pharmaceutical compositions containing them
IT8323205A0 (it) Composizioni farmaceutiche adattivita&#39; antiinfiammatoria e/o analgesica, non ulcerogene.
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
FR2744448B1 (fr) Nouvelles piperidines derivees d&#39;aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
BR9911787A (pt) 1h-indazóis substituìdos por 1,5- e 3-o com efeito antiasmático, antialérgico, inibidor de inflamação, imunomodulador e neuroprotetor, processos para a sua preparação e seu emprego como medicamento
BR9911772A (pt) 1 2-dihidro-indazol-3-onas 1,2,5-trissubstituìdas com eficácia antiasmática, antialérgica, inibidora de inflamações, imunomoduladora e neuroprotetora, processo para sua preparação e sua aplicação como medicamento
FI973229A (fi) Uusi farmaseuttinen koostumus
DE69322750T2 (de) Dibekacin und Arbekacin Derivate wirksam gegen resistente Bakterien, und ihre Herstellung
FI953956A (fi) 2,3-rengaskondensoidut 1,4-dihydropyridiinit, menetelmät niiden valmistamiseksi ja niiden käyttö lääkkeinä
GB2230262B (en) 2-substituted n,n-di-trimethoxybenzoyl piperazines and pharmaceutical uses thereof
IL127518A (en) Substituted heterocyclic benzocycloalkenes, their preparation and pharmaceutical compositions having an analgesic effect
FI961977A0 (fi) N-substituoidut atsabisykloalkaanijohdannaiset, niiden valmistus ja käyttö
BR0016941A (pt) Derivados de aminometil-fenil-ciclohexanona
BR9911178B1 (pt) Derivados de 3-(2-oxo-[1,3&#39;]bipirrolidinil-3-ilidenometil)-cefems, bem como preparação farmacêutica e uso dos mesmos
BR9909529A (pt) Maleato de paroxetina
ITTO950554A0 (it) Diamidi aromatiche acide ad attivita&#39; antigastrinica, procedimento perla loro preparazione e loro uso farmaceutico

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/06/2009, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: BAXTER HEALTHCARE S.A. (CH) , BAXTER INTERNATIONAL

Free format text: TRANSFERIDO DE: ASTA MEDICA AKTIENGESELLSCHAFT

B25A Requested transfer of rights approved

Owner name: ZIOPHARM ONCOLOGY, INC. (US)

Free format text: TRANSFERIDO DE: BAXTER HEALTHCARE S.A. E BAXTER INTERNATIONAL INC.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.